Insilico Medicine was valued at about $895 million after raising $95 million last July from the likes of leading Chinese healthcare-focused firm Qiming Venture Partners and billionaire Eduardo Saverin’s B Capital, among others.
, a Hong Kong and New York-based company that uses AI for drug discovery, has filed for an initial public offering in the Asian financial hub that’s slowly recovering from a drought of major listings.
Insilico Medicine did not disclose details of its IPO in its filing to the Hong Kong stock exchange on Tuesday, although a report by local newspapersaid it’s planning to raise $200 million, citing unnamed sources. The company had previously filed confidentially for a U.S. IPO to raise around $300 million, Bloomberg News reported in November 2021. Insilico Medicine didn’t immediately respond to a comment request.
The biotech company was valued at approximately $895 million after raising $95 million last July from the likes of leading Chinese healthcare-focused firm Qiming Venture Partners and Singapore-based billionaire B Capital. Other investors in the round include U.S. private equity giant Warburg Pincus, as well as the venture capital arm of oil giant Saudi Aramco and Pavilion Capital, a unit of Singapore state-owned investment fund Temasek.WuXi, Sequoia Capital China, Hillhouse, Baidu Ventures and Lilly Asia Ventures, the venture capital firm spun off from Eli Lilly & Co.
Insilico Medicine says it uses generative AI technology to speed up and reduce the cost of discovering novel drugs that target mainly rare diseases. The company is currently focusing on a drug candidate that could treat idiopathic pulmonary fibrosis, a rare lung disease. It’s also working on dozens of other potential medicines for Covid-19 and cancer, among others.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
First AI-generated drug enters human clinical trials, targeting chronic lung disease patientsThe first drug ever generated by artificial intelligence has entered Phase 2 clinical trials with lung disease patients; the first dose was successfully administered to a human, Insilico Medicine announced.
Leer más »
The Most Important Question in MedicineThe most important question in medicine: Ask it often enough, and it will eventually save someone's life. MedTwitter
Leer más »
Penn Medicine to buy shuttered Brandywine Hospital in Chester CountyPenn Medicine has struck a deal to buy the shuttered Brandywine Hospital in Chester County.
Leer más »
Penn Medicine intends to buy shuttered Brandywine HospitalPenn Medicine has signed a letter of intent to buy the Chester County facility - that has been closed for 18 months - by the end of the year.
Leer más »
WSJ News Exclusive | Ecstasy-for-Medicine Advocate MAPS Looks for Cash LifelineMAPS, a nonprofit, is working on an $85 million private share sale to keep itself afloat until mid-2024, when it hopes to start selling MDMA in the U.S.
Leer más »
From Physician to Patient to Reinventing Medicine.HeartBobH interviews JagSinghMD about the COVID journey that led to his book, 'Future Care: Sensors, Artificial Intelligence, and the Reinvention of Medicine.' FutureCare MedTwitter
Leer más »